Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women.

Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL

The Journal of clinical endocrinology and metabolism1 Nov 1993Cited by 89 (Europe PMC)

PMID8077337DOI10.1210/jcem.77.5.8077337PepBankPUB-08077337

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialPharmacokinetics
IGF-I increased serum IGF-I concentrations in postmenopausal women.
In plain wordsIGF-I increased blood IGF-I levels in postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum IGF-I
Study
n = 18
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30, 60, 120, or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Measurements
Serum IGF-I increase
2 to 4 fold
During IGF-I treatment, postmenopausal women
Source sentences
Summary
Serum IGF-I concentrations increased by 2- to 4-fold during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733701
02HumanNon-randomized trialEfficacy outcome
IGF-I increased serum type I procollagen carboxyl-terminal propeptide dose dependently in postmenopausal women.
In plain wordsIn postmenopausal women, higher IGF-I doses increased a marker of collagen production.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseType I procollagen carboxyl-terminal propeptide
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30, 60, 120, or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Measurements
Correlation of serum type I procollagen carboxyl-terminal propeptide with dose (r)
0.85
Postmenopausal women, doses 30-180 micrograms/kg.day
P value for serum type I procollagen carboxyl-terminal propeptide correlation with dose
< 0.001
Postmenopausal women, IGF-I doses 30, 60, 120, or 180 micrograms/kg.day
Source sentences
Summary
There were dose-dependent increases in serum type I procollagen carboxyl-terminal propeptide concentration (r = 0.85, P < 0.001), an index of collagen synthesis, and of urinary excretion of deoxypyridinoline (r = 0.75, P = 0.001), an index of bone collagen breakdown.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733702
03HumanNon-randomized trialEfficacy outcome
IGF-I increased urinary deoxypyridinoline dose dependently in postmenopausal women.
In plain wordsIn postmenopausal women, higher IGF-I doses increased a marker of bone collagen breakdown.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseUrinary deoxypyridinoline
Study
n = 18
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30, 60, 120, or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Measurements
Correlation of urinary deoxypyridinoline excretion with dose (r)
0.75
Postmenopausal women, doses 30-180 micrograms/kg.day
P value for urinary deoxypyridinoline excretion correlation with dose
0.001
Postmenopausal women, IGF-I doses 30, 60, 120, or 180 micrograms/kg.day
Source sentences
Summary
There were dose-dependent increases in serum type I procollagen carboxyl-terminal propeptide concentration (r = 0.85, P < 0.001), an index of collagen synthesis, and of urinary excretion of deoxypyridinoline (r = 0.75, P = 0.001), an index of bone collagen breakdown.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733703
04HumanNon-randomized trialSafety outcome
Hypoglycemia did not occur during IGF-I treatment in postmenopausal women.
In plain wordsPostmenopausal women had no low blood sugar during IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHypoglycemia
Study
n = 18
Outcome group
Adverse events · Metabolic and weight
Studied dose
30, 60, 120, or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
Hypoglycemia did not occur.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733709
05HumanNon-randomized trialSafety outcome
Higher IGF-I doses caused orthostatic hypotension in some postmenopausal women.
In plain wordsHigher IGF-I doses caused low blood pressure when standing in some postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableOrthostatic hypotension
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
120 or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733704
06HumanNon-randomized trialSafety outcome
Higher IGF-I doses caused sinus tachycardia in some postmenopausal women.
In plain wordsHigher IGF-I doses caused a fast heartbeat in some postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableSinus tachycardia
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
120 or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733705
07HumanNon-randomized trialSafety outcome
Higher IGF-I doses caused bilateral parotid discomfort in some postmenopausal women.
In plain wordsHigher IGF-I doses caused discomfort in both parotid glands in some postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableParotid discomfort
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
120 or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733706
08HumanNon-randomized trialSafety outcome
Higher IGF-I doses caused weight gain in some postmenopausal women.
In plain wordsHigher IGF-I doses caused weight gain in some postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseWeight gain
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
120 or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733707
09HumanNon-randomized trialSafety outcome
Higher IGF-I doses caused edema in some postmenopausal women.
In plain wordsHigher IGF-I doses caused swelling in some postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableEdema
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
120 or 180 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733708
10HumanNon-randomized trialEfficacy outcome
Lower IGF-I doses significantly increased serum type I procollagen carboxyl-terminal propeptide in postmenopausal women.
In plain wordsLower IGF-I doses increased a marker of collagen production in postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseProcollagen propeptide at lower doses
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 or 60 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
However, treatment at the 2 lower dosages increased serum type I procollagen carboxyl-terminal propeptide significantly and produced minimal or no side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733710
11HumanNon-randomized trialSafety outcome
Lower IGF-I doses produced minimal or no side effects in postmenopausal women.
In plain wordsLower IGF-I doses produced few or no side effects in postmenopausal women.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedSide effects at lower doses
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
30 or 60 micrograms/kg.day · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
However, treatment at the 2 lower dosages increased serum type I procollagen carboxyl-terminal propeptide significantly and produced minimal or no side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days.
Report a problemFND-0807733711

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.